Low bleed implantable prosthesis with a taper

Information

  • Patent Grant
  • 11622871
  • Patent Number
    11,622,871
  • Date Filed
    Tuesday, July 23, 2019
    5 years ago
  • Date Issued
    Tuesday, April 11, 2023
    a year ago
Abstract
A vascular graft having a sealing layer and a tapered length portion. The sealing layer provides the vascular graft with low bleed characteristics subsequent to a needle puncture such as with a dialysis needle or a suture needle. The sealing layer in the tapered length portion has varying wall thickness along the tapered length portion.
Description
FIELD

The present disclosure relates to implantable devices such as vascular grafts, and more particularly, relates to low bleed tubular vascular grafts with a tapered length portions such that opposing ends of the graft have different inside diameters.


BACKGROUND

The use of implantable medical devices in the treatment of diseased vasculature and other body conduits has become commonplace in the medical field. These implantable devices can be used in applications where a low bleed implantable device is desired wherein the implantable device may be punctured (e.g., by suture needles and/or dialysis needles) and upon subsequent removal of the puncturing needle there is minimal fluid loss at the needle puncture site. Some of these implantable medical devices (e.g., a graft) may also be used in applications (e.g., dialysis) where a graft may benefit from a taper portion along its length, whereby one end of the graft has a larger inside diameter than an opposing end. A typical graft that has been designed for needle puncture may include an elastomeric material (e.g., silicone) that has a consistent wall thickness along the length of the graft. A typical graft, for example, a porous expanded polytetrafluoroethylene (ePTFE) graft that has been manufactured with a taper has a wall thickness at large end of the taper that is less than a wall thickness at a small end of the taper, therefore potentially limiting flexibility.


These tapered grafts and low bleed grafts have functioned well in many applications, particularly for dialysis applications. These previously known grafts still have limitations and leave room for improvements, especially in difficult applications such as where a low bleed graft and a taper is desired. Therefore, it remains desirable to provide a low bleed taper graft that has desirable handling attributes. There remains a need among vascular surgeons for such a graft.


SUMMARY

This document describes an implantable medical device, such as a vascular graft, incorporating a taper length portion and having low bleed characteristics following puncture by and removal of a needle such as a dialysis needle or a suture needle. A vascular graft per this disclosure may comprise a tubular structure having a first (Inner) layer, an intermediate layer, an optional second (outer) layer, and a length wherein said intermediate layer comprises an elastomer; wherein said tubular structure has a proximal end with proximal inside and outside diameters, and a distal end with a distal inside and outside diameters, wherein the distal inner and outer diameters are greater than the proximal inside and outside diameters respectively, and there is a transition length portion located between the proximal diameters and the distal diameters; and wherein the intermediate layer has a variable thickness along the length of the tubular structure and particularly along the transition length portion, wherein the thickness of the intermediate layer is greater at the distal end than it is at the proximal end. The first inner layer and the second outer layer may, in contrast to the intermediate layer (and counterintuitively), also be of variable thickness along the transition length portion but vary from being thicker at the proximal end to thinner at the distal end.


It is apparent that additional layers of materials as desired may be added to the three layer constructs described herein, resulting in constructs having four, five, six or more layers. In one embodiment, a first, inner layer may be a porous (e.g., ePTFE) material, an intermediate layer may be a non- porous (e.g., an elastomer) material, and an optional second, outer layer may be a porous (e.g., ePTFE) material. All materials should be suitable implantable materials. Suitable porous materials in addition to ePTFE may, for example, include implantable fabrics (e.g., polyethylene terephthalate) and porous polyurethanes and polyethylenes. Intermediate layer materials may include elastomers such as silicones and polyurethanes. These intermediate layer materials would most typically be non-porous materials, but porous versions of these same materials may also be used for this layer.


As layers extend along proximal, transition, and distal length portions; the materials making up the various layers may extend continuously and integrally between opposing ends of the graft. Alternatively, the various layers may be discreet, resulting in material boundaries between various length portions.





BRIEF DESCRIPTION OF THE DRAWINGS

The accompanying drawings are included to provide a further understanding of the present disclosure and are incorporated in and constitute a part of this specification, illustrate embodiments of the present disclosure, and together with the description serve to explain the principles of the present disclosure.



FIG. 1 shows an isometric view of human anatomy with an implantable device.



FIG. 2 shows a longitudinal cross section of a previously known implantable device with low bleed characteristics.



FIG. 3A shows a longitudinal cross section side view of an implantable device in accordance with the present disclosure.



FIG. 3B shows a longitudinal cross section side view of an implantable device in accordance with the present disclosure.



FIG. 3C shows a longitudinal cross section side view of an implantable device in accordance with the present disclosure.



FIG. 4 shows a transverse cross section taken at a designated location on the longitudinal cross section of FIG. 3A.



FIG. 5 shows another transverse cross section taken at a designated location on the longitudinal cross section of FIG. 3A.





DETAILED DESCRIPTION

An implantable device (e.g., a vascular graft) in accordance with the present disclosure may be used in various applications. The implantable device 100 may be used in an arterial venous application (e.g., dialysis) as shown by example in FIG. 1. The implantable device (e.g., graft) 100 may have a distal end 102 that may be in communication with venous vasculature 104 and a proximal end 106 that may be in communication with arterial vasculature 112 and a length between the proximal end and the distal end. The graft may have a tubular shape along the length of the graft. The implantable device 100 could also be a stent-graft or a hybrid of a stent-graft and a vascular graft.



FIG. 2 shows a longitudinal cross section of a portion of a length of previously known vascular graft with a first (inner) layer 200, an intermediate layer 202, and a second (outer) layer 206. The intermediate layer 202 (which may, for example, be an elastomer layer) is shown to have a constant wall thickness along the length of the vascular graft.


An implantable device 100 can have various configurations. For example, as shown in the longitudinal cross section of FIGS. 3A-C and the transverse cross sections of FIG. 4 and FIG. 5, the implantable device 100 (e.g., a low bleed vascular graft) has a distal portion distal end 102 with a distal portion outer diameter 108 and a distal portion inside diameter 113. The implantable device 100, as shown in FIGS. 3A-C, has a proximal portion proximal end 106 with a proximal portion outer diameter 110 that is smaller than distal portion outer diameter 108 and a proximal portion inside diameter 111 that is smaller than the distal portion inside diameter 113. Located between the proximal portion proximal end 106 and the distal portion distal end 102, the implantable device 100 may have a proximal portion 322, a tapered transition portion 308, and a distal portion 338. In one application, for example, in a dialysis application, the proximal portion proximal end 106 may be in communication with an artery and the distal portion distal end 102 may be in communication with a vein. Alternatively, the proximal portion proximal end 106 may be in communication with a vein and the distal portion distal end 102 may be in communication with an artery. In other examples, the implantable device 100 may consist entirely of a transition portion 308, meaning the implantable device 100 is tapered entirely along its length between the proximal end 106 and the distal end 102.


The transition portion 308 has a transition portion length 324 between a transition portion proximal end 304 and transition portion distal end 300. The transition portion 308 may comprise a first (inner) layer 310 having a transition portion first layer wall thickness 312. The transition portion first layer wall thickness 312 may vary along the transition portion length 324. The transition portion first layer wall thickness 312 may be thicker on the transition portion proximal end 304 than the transition portion first layer wall thickness 312 at the transition portion distal end 300. Alternatively, the transition portion first layer wall thickness 312 may be thinner on the transition portion proximal end 304 than the transition portion first layer wall thickness 312 at the transition portion distal end 300.


The first layer 310 has a first layer first surface 358 and a first layer second surface 360, as shown in FIGS. 3A-C. The first layer first surface 358 and the first layer second surface 360 may extend along the implantable device 100 (e.g., along the proximal portion 322, transition portion 308, and the distal portion 338 or a combination thereof). As shown by example in FIGS. 3A-C, the first layer first surface 358 and the first layer second surface 360 extend along the proximal portion 322, transition portion 308, and the distal portion 338.


The transition portion 308 may also have an intermediate layer 314 adjacent to at least a portion of the first layer 310. For example, as shown in FIGS. 3A-C, the transition portion 308 has an intermediate layer 314 adjacent to or juxtaposed to the first layer second surface 360. Alternatively, the intermediate layer 314 may be partially imbibed into porous first layer 310 near the interface of those two layers. In one example, the intermediate layer 314 is an elastomer (e.g., silicone), and the first layer 310 is a porous polymer (e.g., ePTFE).


The intermediate layer 314 has a transition portion intermediate layer wall thickness 316 that varies along the transition portion 308. The transition portion intermediate layer wall thickness 316 may taper between the transition portion proximal end 304 and the transition portion distal end 300 as shown in FIGS. 3A-B. The transition portion intermediate layer wall thickness 316 may be thinner near the transition portion proximal end 304 than the transition portion distal end 300. Alternatively, the transition portion intermediate layer wall thickness 316 may be thicker at the transition portion proximal end 304 than the transition portion distal end 300.


The intermediate layer 314 may also be juxtaposed to an optional additional layer (e.g., second layer 318). Alternatively, the intermediate layer 314 may be partially imbibed into another layer, for example, the second porous layer 318, in the surface region of the second layer 318 that is adjacent to the intermediate layer 314. The intermediate layer 314 may extend proximally and/or distally beyond the transition portion 308.


The transition portion 308 may have a second (outer) layer 318. For example, as shown in FIGS. 3A-C, the transition portion 308 has a second layer 318, adjacent to the intermediate layer 314, with a transition portion second layer wall thickness 320. The transition portion second layer wall thickness 320 may taper between the transition portion proximal end 304 and the transition portion distal end 300, as shown in FIGS. 3A-C. The transition portion intermediate layer wall thickness 316 may be thicker near the transition portion proximal end 304 than near the transition portion distal end 300. Alternatively, the transition portion proximal end 304 may be thinner than the transition portion distal end 300. The second layer 318 may extend proximally and/or distally beyond the transition portion 308.


In certain instances, the intermediate layer 314 may taper between the transition portion proximal end 304 and the transition portion distal end 300. In certain instances, the intermediate layer 314 may taper such that the intermediate layer wall thickness 316 is zero or approximately zero at any point within the transition portion length 324 (as is represented by the dotted lines showing the boundary of the intermediate layer 314). In certain instances, the intermediate layer 314 may taper such that the intermediate layer wall thickness 316 is zero or approximately zero the at the transition portion proximal end 304. As shown in FIG. 3B, the intermediate layer 314 tapers at a constant rate toward the transition portion proximal end 304. In certain instances, the taper of the intermediate layer wall thickness 316 between the transition portion proximal end 304 and the transition portion distal end 300 may be non-constant and may increase or decrease in rate as it approaches the transition portion proximal end 304. As shown in FIG. 3B, the proximal portion 322 does not include the intermediate layer 314. The lack of the intermediate layer 314 being present in the proximal portion 322 (and/or the decrease in thickness of the intermediate layer 314 in the transition portion length 324) may enhance the ease of puncture of the proximal portion 322 (or the transition portion length 324) by a suture (or the like) to secure the implantable device 100 to a patient. In certain instances, the transition portion second layer wall thickness 320 may increase in thickness toward the transition portion proximal end 304 as the intermediate layer wall thickness 316 decreases in thickness (e.g., as shown in FIG. 3B). In other instances, the transition portion first layer wall thickness 312 may increase in thickness toward the transition portion proximal end 304 as the intermediate layer wall thickness 316 decreases in thickness. In other instances, an overall wall thickness of the implantable device 100 within the transition portion length 324 may decrease as the intermediate layer wall thickness 316 decreases.


Also as shown in FIGS. 3A-C, the implantable device 100 may have a distal portion 338 between the transition portion distal end 300 and a distal portion distal end 102. The distal portion 338 may have varying diameters (inside and/or outside) along the distal portion 338 or it may have constant diameters. For example, the distal portion 338 has a constant distal portion outer diameter 108 between the distal portion distal end 102 and the transition portion distal end 300, as shown in FIGS. 3A-C. The distal portion 338 may have a constant distal portion inside diameter 113 between the distal portion distal end 102 and the transition portion distal end 300. The distal portion 338 may comprise a first layer 310 having a distal portion first layer wall thickness 344, an intermediate layer 314 having a distal portion intermediate layer wall thickness 348, and a second layer 318 having a distal portion second layer wall thickness 352.


Also as shown in FIGS. 3A-C, the implantable device 100 may have a proximal portion 322 between a proximal portion proximal end 106 and transition portion proximal end 304. The proximal portion 322 may have varying diameters (inside and/or outside) along the proximal portion 322 or it may have constant diameters. For example, the proximal portion 322 has the same proximal portion outer diameter 110 between the proximal portion proximal end 106 and the transition portion proximal end 304, as shown in FIGS. 3A-C. The proximal portion 322 may have a proximal portion inside diameter 111 that is constant between the proximal portion proximal end 106 and the transition portion proximal end 304 or alternatively, may have a varying proximal portion inside diameter 111. The proximal portion 322 may comprise a proximal portion first layer 310 having a proximal portion first layer wall thickness 328, a proximal portion intermediate layer 314 having a proximal portion intermediate layer wall thickness 332, and a proximal portion second layer 318 having a proximal portion second layer wall thickness 336.


In certain instances, the proximal portion intermediate layer 314 may taper between the transition portion proximal end 304 and the proximal end 106. In certain instances, the intermediate layer 314 may taper such that the intermediate layer wall thickness 332 is zero or approximately zero at any point within the proximal portion length 325 (as is represented by the dotted lines showing the boundary of the intermediate layer 314). In certain instances, the intermediate layer 314 may taper such that the intermediate layer wall thickness 332 is zero or approximately zero the at the proximal end 106. The decrease in thickness of the intermediate layer 314 in the proximal portion 322 may enhance the ease of puncture of the proximal portion 322 by a suture (or the like) to secure the implantable device 100 to a patient. As shown in FIG. 3C, the intermediate layer 314 tapers at a constant rate toward the proximal end 304. In certain instances, the taper of the intermediate layer wall thickness 332 between the transition portion proximal end 304 and the proximal end 106 may be non-constant and may increase or decrease as it approaches the proximal end 106. In certain instances, the proximal portion first layer wall thickness 328 may increase in thickness toward the proximal end 106 as the proximal portion intermediate layer 314 decreases in thickness (e.g., as shown in FIG. 3C). In other instances, the proximal portion second layer wall thickness 336 may increase in thickness toward the proximal end 106 as the intermediate layer wall thickness 332 decreases in thickness. In other instances, an overall wall thickness of the implantable device 100 within the proximal portion length 325 may decrease as the intermediate layer wall thickness 332 decreases.


The transition portion 308 has a transition portion proximal end 304 (FIG. 5) with a transition portion proximal end outer diameter 306 and a transition portion proximal end inside diameter 307. The implantable device 100 also has a transition portion distal end 300 (FIG. 4) with a transition portion distal end outer diameter 302, and a transition portion distal end inside diameter 303. The transition portion distal end diameters (302,303) may be the same diameter as distal portion distal end diameters (108,113). The transition portion proximal end diameters (306,307) may be the same diameter as proximal portion proximal end diameters (110,111).


The proximal portion 322 may have various wall thickness configurations. In one example, as shown in FIG. 3A, the proximal portion 322 has a first layer 310, an intermediate layer 314, and a second layer 318. The first layer 310 has a proximal portion first layer wall thickness 328 that is substantially the same thickness along the proximal portion 322 and meets the transition portion first layer wall thickness 312 at the transition portion proximal end 304. The intermediate layer 314 has a proximal portion intermediate layer wall thickness 332 that is substantially the same thickness along the proximal portion 322 and meets the transition portion intermediate layer wall thickness 316 at the transition portion proximal end 304. The second layer 318 has a proximal portion second layer wall thickness 336 that is substantially the same thickness along the proximal portion 322 and meets the transition portion second layer wall thickness 320 at the transition portion proximal end 304. Alternatively, the proximal portion 322 may have wall thicknesses that are not constant along the proximal portion length 325.


The distal portion 338 may have various wall thickness configurations. In one example, as shown in FIGS. 3A-C, the distal portion 338 has a first layer 310, an intermediate layer 314, and a second layer 318. The first layer 310 has a distal portion first layer wall thickness 344 that is substantially the same thickness along the distal portion 338 and meets the transition portion first layer wall thickness 312 at the transition portion distal end 300. The intermediate layer 314 has a distal portion intermediate layer wall thickness 348 that is substantially the same thickness along the distal portion 338 and meets the transition portion intermediate layer wall thickness 316 at the transition portion distal end 300. The second layer 318 has a distal portion second layer wall thickness 352 that is substantially the same thickness along the distal portion 338 and meets the transition portion second layer wall thickness 320 at the transition portion distal end 300. Alternatively, the distal portion 338 may have wall thicknesses that are not constant along the distal portion length 326.


The implantable device 100 may have various overall wall thickness configurations. For example, as shown in FIG. 4, the transition portion 308 (also shown in FIGS. 3A-C) may have a transition portion distal end overall wall thickness 354 at the transition portion distal end 300 that is less than a transition portion proximal end overall wall thickness 356 at the transition portion proximal end 304. The transition portion overall wall thickness at a location along the transition portion may vary between transition portion overall wall thicknesses (354,356).


An overall wall thickness measured along the implantable device 100 may comprise at least one polymer layer (e.g., ePTFE) and at least one elastomer layer (e.g., silicone). The implantable device 100 may have a transition portion 308 comprising a transition portion overall wall thickness 354 (as shown in FIG. 4). A transition portion wall thickness ratio, taken along the transition portion 308 (e.g., at transition portion distal end 300), of transition portion intermediate layer wall thickness 316 to a combination of transition portion first layer wall thickness 312 and transition portion second layer wall thickness 320 is equal to 1. In other words, this ratio is the ratio of the intermediate layer wall thickness to the combination of the inner and outer layer wall thicknesses. In other cases, the transition portion distal end wall thickness ratio may be greater than 1.0, for example, 1.1, 1.2, 1.3, 1.4, 1.5 or even greater. Still, in other cases, the transition portion wall thickness ratio may be less than 1.0, for example, 0.7, 0.8, or 0.9.


The implantable device 100 may also have a transition portion 308 comprising a transition portion overall wall thickness 356 (FIG. 5). A transition portion wall thickness ratio, taken along the transition portion 308 (e.g., at transition portion proximal end 304), of the transition portion intermediate layer wall thickness 316 to a combination of the transition portion first layer wall thickness 312 and the transition portion second layer wall thickness 320 is less than 1. For example, the transition portion proximal end ratio of the transition portion intermediate layer wall thickness 316 to a combination of the transition portion first layer wall thickness 312 and the transition portion second layer wall thickness 320 may be 0.9, 0.8, 0.7, 0.6, 0.5, 0.4 or less. The transition portion proximal end ratio may extend along the implantable device 100 to a proximal portion 322, as shown in FIG. 3A. Similarly, the transition portion distal end ratio may extend along the implantable device 100 to a distal portion 338, also as shown in FIG. 3A.


In addition to the ratios described above, the overall wall thickness 356 at the transition portion proximal end 304 may be greater than the overall wall thickness 354 at the transition portion distal end 300.


The implantable device 100 may have various portions. For example, it may have a proximal portion 322 with a proximal portion length 325, a transition portion 308 with a transition portion length 324, and a distal portion 338 with a distal portion length 326, as shown in FIGS. 3A-C. The proximal portion length 325 may be shorter than the transition portion length 324 and the transition portion length 324 may be shorter than the distal portion length 326. The distal portion length 326 may be 15 cm, 20 cm, 30 cm, 40 cm, 50 cm or more, and the transition portion length 324 may be 5 cm (other lengths may range from 1 cm to 10 cm), and the proximal portion length 325 may be approximately 2 cm (other lengths may range from 1 cm to 10 cm). Other combinations of lengths are contemplated and dependent upon application. In some cases, the implantable device 100 may be entirely a transition portion 308 (i.e., the entire graft is tapered) and therefore may have a transition portion length 324 of 20 cm, 30 cm, 40 cm, or 50 cm or more.


An implantable device 100 may be manufactured in various ways. One example is described herein, as follows. A 145 cm long mandrel having a 7 mm diameter portion by 120 cm long, a 3.84 mm diameter portion by 20 cm long, and a 5 cm long tapered portion between the 7 mm diameter portion and the 3.84 mm diameter portion was obtained (i.e., a 7-4 mm tapered mandrel). A 3.60 mm diameter extruded ePTFE tube with a wall thickness of 0.08 mm was obtained (ePTFE first tube). The ePTFE first tube has a lumen extending along the ePTFE first tube. The 7-4 mm tapered mandrel was then inserted into the ePTFE first tube. The ePTFE first tube was extended so that any wrinkling of the ePTFE first tube was minimized. The ePTFE first tube was then helically wrapped with a 1.27 cm wide ePTFE film tape entirely along the length of the ePTFE first tube. The mandrel with the ePTFE first tube was then heated in a convection oven at 370 degrees C. for 12 minutes. Following removal from the oven, the ePTFE first tube on the 7-4 mm tapered mandrel was then allowed to air cool in ambient air until the ePTFE tube reached approximately room temperature. This example produced an ePTFE first tube with approximately a 7 mm inside diameter length portion, a 4 mm inside diameter length portion, and a tapered length portion extending between the 7 mm inside diameter length portion and the 4 mm inside diameter length portion. The 7 mm inside diameter length portion had a wall thickness of approximately 0.08 mm and the 4 mm inside diameter length portion had a wall thickness of approximately 0.10 mm. The tapered length portion had a varying wall thickness (i.e., varying from 0.08 mm to 0.10 mm) between the 7 mm inside diameter length portion and the 4 mm inside diameter length portion.


A second ePTFE tube with a taper was manufactured as follows. A 145 cm long mandrel with a 6.50 mm diameter portion by 110 cm long, a 3.80 mm diameter portion by 30 cm long, and a 5 cm long tapered length portion between the 6.50 mm diameter length portion and the 3.80 mm diameter length portion was obtained (6.5 −3.80 mm tapered mandrel). A 6 mm diameter extruded and expanded ePTFE tube with a wall thickness of 0.66 mm was obtained (ePTFE second tube). The 6.50−3.80 mm tapered mandrel was inserted into the ePTFE second tube lumen. The ePTFE second tube was extended so that any wrinkling of the ePTFE second tube was minimized. The ends of the ePTFE second tube were then secured to the mandrel by wrapping an ePTFE film around the ends of the ePTFE second tube. The ePTFE second tube was then helically wrapped with a 1.90 cm wide ePTFE film tape entirely along the length of the ePTFE second tube. The mandrel with the ePTFE second tube was then heated by a convection oven at 370 degrees C. for 12 minutes. Following removal from the oven, the ePTFE second tube on the mandrel was then allowed to air cool in ambient air until the ePTFE second tube and mandrel reached approximately room temperature. The ePTFE second tube was then removed from the mandrel. This procedure resulted in an ePTFE second tube with a 6.5 mm inside diameter length portion, a 3.80 mm inside diameter length portion, and a tapered length portion extending between the 6.50 mm inside diameter length portion and the 3.80 mm inside diameter length portion. The 6.50 mm inside diameter length portion had a wall thickness of approximately 0.76 mm and the 3.80 mm inside diameter length portion had a wall thickness of approximately 0.79 mm. The tapered length portion had a varying wall thickness that tapered between the wall thickness of the 6.50 mm inside diameter length portion and the wall thickness of the 3.80 mm inside diameter length portion. In certain instances, the tapered length portion had a varying wall thickness that tapered between the wall thickness of the 6 mm inside diameter length portion and the wall thickness of the 4 mm inside diameter length portion, and in other instances, the tapered length portion had a varying wall thickness that tapered between the wall thickness of the 5 mm inside diameter length portion and the wall thickness of the 4 mm inside diameter length portion.


The mandrel with the ePTFE first tube was then coated with a layer of silicone (NuSil Technology LLC, Carpinteria, Calif.). An iris apparatus (Standa Ltd., Vilnius, Lithuania) capable of dilating and contracting between 1 mm and 15 mm was obtained. The mandrel with the first ePTFE tube was displaced through the iris contained within an apparatus. The apparatus supplied silicone to the outer surface of the ePTFE first tube and the iris maintained a wall thickness of silicone of approximately 0.53 mm on the ePTFE first tube outer surface (along the larger diameter portion of the ePTFE first tube), 0.30 mm on the smaller diameter portion of the ePTFE first tube, and a varying silicone wall thickness between 0.53 mm and 0.30 mm along the tapered portion of the ePTFE first tube. The silicone was then allowed to partially set by curing in a convection oven for 6.5 minutes at 200 degrees C.


The ePTFE second tube was then enlarged diametrically by pulling the ePTFE second tube over a mandrel. The mandrel had a 9.60 mm outside diameter length portion of approximately 55 cm length and a 5.40 mm outside diameter length portion of 12 cm length with a transition length portion extending between the 5.40 mm outside diameter length portion and the 9.60 mm outside diameter length portion. The ePTFE second tube and mandrel assembly was then heated in a convection oven for approximately 45 seconds at 200 degrees C. The ePTFE second tube distal end inside diameter was enlarged to approximately 9.60 mm over the ePTFE second tube distal end and the ePTFE second tube proximal end inside diameter was enlarged to approximately 5.40 mm on the ePTFE second tube proximal end with the transition length portion extending between the 9.60 mm inside diameter and the 5.40 mm inside diameter.


After the ePTFE second tube was removed from the mandrel, a flare of 12 mm was then created on the ePTFE second tube distal end (i.e., 9.60 mm inside diameter end) with a flaring tool (a mandrel). The ePTFE second tube was then held within the apparatus with the iris to allow the ePTFE first tube with its outer layer of silicone to be inserted into the lumen of the ePTFE second tube. The ePTFE first tube proximal portion was inserted first through the ePTFE second tube distal portion until the transition length portions of the ePTFE first tube and ePTFE second tube were approximately aligned. While the ePTFE first tube was being inserted through the ePTFE second tube the apparatus applied a second layer of silicone approximately 0.15 mm thick (the second layer being thinner than the first layer) onto the ePTFE first tube with silicone outer layer. The second layer of silicone wall thickness was controlled by the iris apparatus. After the second layer of silicone was applied and the ePTFE first tube and ePTFE second tube tapered portions were aligned, the silicone was then allowed to fully set by curing in a convection oven for 15 minutes at 200 degrees C. In this example, an implantable device according to this disclosure was made.


The resulting implantable device had a first layer comprising an ePTFE first (Inner) tube, an intermediate layer comprising silicone, and a second layer comprising an ePTFE second (outer) tube. The implantable device had a transition length portion with a length of 5 cm, a distal length portion with a length of 48 cm and a proximal length portion with a length of 2 cm. Longitudinal cross sections were taken and wall thickness measurements were made (overall wall thickness and intermediate layer wall thickness) with an optical profiler (Unitron Inc., Bohemia N.Y.) along the proximal length portion and the distal length portion of the implantable device. The overall wall thickness in the proximal length portion was approximately 1.25 mm. The intermediate layer wall thickness in the proximal length portion was approximately 0.48 mm. The overall wall thickness in the distal length portion was approximately 1.22 mm and the intermediate layer wall thickness in the distal length portion was 0.70 mm. The overall wall thickness in the transition length portion varied from 1.25 mm near the proximal length portion to 1.22 mm near the distal length portion and the intermediate layer wall thickness in the transition length portion varied from 0.48 mm near the proximal length portion to 0.70 mm near the distal length portion. A ratio of intermediate layer wall thickness to a combination of the ePTFE first tube wall thickness and ePTFE second tube wall thickness in the proximal length portion was approximately 0.63. A ratio of intermediate layer wall thickness to a combination of the ePTFE first tube wall thickness and ePTFE second tube wall thickness in the distal length portion was approximately 1.35 mm.


Implantable devices according to this disclosure may be used in various applications. For example, the implantable device may be used in an arterial venous application such as in dialysis. One end of the implantable device may be attached to a vein, an opposing end may be attached to an artery.


In addition to the teachings described above and claimed below, devices and/or methods having different combinations of the features described above and claimed below are contemplated. As such, the description is also directed to other devices and/or methods having any other possible combination of the dependent features claimed below.


Numerous characteristics and advantages have been set forth in the preceding description, including various alternatives together with details of the structure and function of the devices and/or methods. The disclosure is intended as illustrative only and as such is not intended to be exhaustive. It will be evident to those skilled in the art that various modifications may be made, especially in matters of structure, materials, elements, components, shape, size and arrangement of parts including combinations within the principles of the invention, to the full extent indicated by the broad, general meaning of the terms in which the appended claims are expressed. To the extent that these various modifications do not depart from the spirit and scope of the appended claims, they are intended to be encompassed therein.

Claims
  • 1. A vascular graft comprising: a tubular structure formed of a first layer, a second layer, and a third layer with at least one of the first layer and the third layer including a porous structure and the second layer being formed of an elastomeric material and being arranged between the first layer and the third layer, the tubular structure having: a proximal portion including the first layer having a proximal portion thickness, the second layer having a proximal portion thickness, and the third layer having a proximal portion thickness; anda distal portion including at least a section that is of a greater diameter than a diameter of the proximal portion and including the first layer has a distal portion thickness, the second layer has a distal portion thickness, and the third layer has a distal portion thickness with the distal portion thickness of the second layer being greater than the proximal portion thickness of the second layer.
  • 2. The vascular graft of claim 1 wherein at least one of the first layer and the third layer comprises ePTFE.
  • 3. The vascular graft of claim 2, wherein at second layer comprises silicone.
  • 4. The vascular graft of claim 1, wherein a thickness of the second layer decreases as one or both of a thickness of the first layer and a thickness of the second layer increases.
  • 5. The vascular graft of claim 4, wherein the thickness of the second layer decreases within the proximal portion.
  • 6. The vascular graft of claim 5, wherein the thickness of the second layer decreases to a minimum thickness that is approximately zero.
  • 7. The vascular graft of claim 5, wherein the thickness of the second layer decreases to a minimum thickness prior to an end of the proximal portion.
  • 8. The vascular graft of claim 5, wherein the thickness of the second layer decreases to a minim um thickness at an end of the proximal portion.
  • 9. The vascular graft of claim 1, wherein a diameter of the proximal portion decreases in thickness as a thickness of the second layer decreases within the proximal portion.
  • 10. A vascular graft comprising: a tubular structure formed of a first layer, a second layer, and a third layer with the second layer being arranged between the first layer and the third layer, the tubular structure having: a proximal portion including the first layer having a proximal portion thickness, the second layer having a proximal portion thickness, and the third layer having a proximal portion thickness; anda distal portion increasing in diameter relative to the proximal portion and including the first layer has a distal portion thickness, the second layer has a distal portion thickness, and the third layer has a distal portion thickness with the distal portion thickness of the second layer being greater than the proximal portion thickness of the second layer.
  • 11. The vascular graft of claim 10, wherein the second layer decreases in thickness within the proximal portion to facilitate needle puncture through the tubular structure.
  • 12. The vascular graft of claim 10, wherein the at least one of the first layer and the third layer including a porous structure and the second layer is formed of an elastomeric material.
  • 13. The vascular graft of claim 10, wherein a thickness of the second layer decreases as one or both of a thickness of the first layer and a thickness of the second layer increases.
  • 14. The vascular graft of claim 13, wherein the thickness of the second layer decreases within the proximal portion.
  • 15. The vascular graft of claim 13, wherein the thickness of the second layer decreases to a minim um thickness that is approximately zero.
  • 16. The vascular graft of claim 13, wherein the thickness of the second layer decreases to a minim um thickness prior to an end of the proximal portion.
  • 17. The vascular graft of claim 10, wherein a diameter of the proximal portion decreases in thickness as a thickness of the second layer decreases within the proximal portion.
  • 18. A method of implanting a vascular graft, the method com prising: arranging a tubular structure within a patient, the tubular structure being formed of a first layer, a second layer, and a third layer with at least one of the first layer and the third layer including a porous structure and the second layer being formed of an elastomeric material and being arranged between the first layer and the third layer and having a proximal portion including the first layer having a proximal portion thickness, the second layer having a proximal portion thickness, and the third layer having a proximal portion thickness; and a distal portion including at least a section that is of a greater diameter than the proximal portion and including the first layer has a distal portion thickness, the second layer has a distal portion thickness, and the third layer has a distal portion thickness with the distal portion thickness of the second layer being greater than the proximal portion thickness of the second layer;puncturing the proximal portion of the tubular structure with a suture to secure the tubular structure to the patient.
  • 19. The method of claim 18, wherein a diameter of the proximal portion decreases in thickness as a thickness of the second layer decreases within the proximal portion.
  • 20. The method of claim 18, wherein the thickness of the second layer decreases within the proximal portion.
CROSS-REFERENCE TO RELATED APPLICATION

This application is a continuation of U.S. patent application Ser. No. 15/173,361, filed Jun. 3, 2016, which claims the benefit of U.S. Provisional Application 62/171,694, filed Jun. 5, 2015, both of which are incorporated herein by reference in their entireties for all purposes.

US Referenced Citations (212)
Number Name Date Kind
512151 Briggs Jan 1894 A
3425418 Chvapil et al. Feb 1969 A
3814137 Martinez Jun 1974 A
3914802 Reick Oct 1975 A
3953566 Gore Apr 1976 A
4133927 Tomodoa et al. Jan 1979 A
4177334 Okita Dec 1979 A
4187390 Gore Feb 1980 A
4193138 Okita Mar 1980 A
4208745 Okita Jun 1980 A
4229838 Sumitomo Oct 1980 A
4279245 Takagi et al. Jul 1981 A
4283448 Bowman Aug 1981 A
4304010 Mano Dec 1981 A
4321711 Mano Mar 1982 A
4347204 Takagi et al. Aug 1982 A
4416028 Eriksson et al. Nov 1983 A
4443511 Worden et al. Apr 1984 A
RE31618 Mano Jul 1984 E
4474630 Planck et al. Oct 1984 A
4478898 Kato Oct 1984 A
4550447 Seiler, Jr. et al. Nov 1985 A
4604762 Robinson Aug 1986 A
4613544 Burleigh Sep 1986 A
4619641 Schanzer Oct 1986 A
4657544 Pinchuk Apr 1987 A
4687482 Hanson Aug 1987 A
4692369 Nomi Sep 1987 A
4731073 Robinson Mar 1988 A
4739013 Pinchuk Apr 1988 A
4743252 Martin, Jr. et al. May 1988 A
4743480 Campbell et al. May 1988 A
4759757 Pinchuk Jul 1988 A
4787921 Shibata et al. Nov 1988 A
4804381 Turina et al. Feb 1989 A
4810749 Pinchuk Mar 1989 A
4816339 Tu et al. Mar 1989 A
4850999 Planck Jul 1989 A
4857069 Kira Aug 1989 A
4871361 Kira Oct 1989 A
4875468 Krauter et al. Oct 1989 A
4877661 House et al. Oct 1989 A
4882113 Tu et al. Nov 1989 A
4891407 Mitchell Jan 1990 A
4921495 Kira May 1990 A
4932964 Bittmann et al. Jun 1990 A
4945125 Dillon et al. Jul 1990 A
4955899 Dealla Coma et al. Sep 1990 A
4957669 Primm Sep 1990 A
4969896 Shors Nov 1990 A
4973609 Browne Nov 1990 A
5024671 Tu et al. Jun 1991 A
5026513 House Jun 1991 A
5061276 Tu et al. Oct 1991 A
5064593 Tamaru et al. Nov 1991 A
5066683 Dillon et al. Nov 1991 A
5071609 Tu et al. Dec 1991 A
5084065 Weldon et al. Jan 1992 A
5099557 Engelsberg Mar 1992 A
5100422 Berguer et al. Mar 1992 A
5104400 Berguer et al. Apr 1992 A
5116360 Pinchuk et al. May 1992 A
5123151 Uehara et al. Jun 1992 A
5123917 Lee Jun 1992 A
5128092 Asaumi et al. Jul 1992 A
5133742 Pinchuk Jul 1992 A
5152782 Kowligi et al. Oct 1992 A
5192310 Herweck et al. Mar 1993 A
5217797 Knox et al. Jun 1993 A
5229431 Pinchuk Jul 1993 A
5290271 Jernberg Mar 1994 A
5320888 Stevens Jun 1994 A
5354329 Whalen Oct 1994 A
5358516 Myers et al. Oct 1994 A
5370681 Herweck et al. Dec 1994 A
5453235 Calcote et al. Sep 1995 A
5466252 Soukup et al. Nov 1995 A
5476589 Bacino Dec 1995 A
5584876 Bruchman et al. May 1996 A
5527353 Schmitt Jun 1996 A
5529820 Nomi et al. Jun 1996 A
5549664 Hirata et al. Aug 1996 A
5556426 Popadiuk et al. Sep 1996 A
5607478 Lentz et al. Mar 1997 A
5609624 Kalis Mar 1997 A
5620763 House et al. Apr 1997 A
5628782 Myers et al. May 1997 A
5628788 Pinchuk May 1997 A
5641373 Shannon et al. Jun 1997 A
5647400 Jani et al. Jul 1997 A
5665114 Weadock et al. Sep 1997 A
5700287 Myers et al. Dec 1997 A
5708044 Branca Jan 1998 A
5716395 Myers et al. Feb 1998 A
5716660 Weadock et al. Feb 1998 A
5718973 Lewis et al. Feb 1998 A
5735892 Myers et al. Apr 1998 A
5749880 Banas et al. May 1998 A
5788626 Thompson Aug 1998 A
5789047 Sasaki et al. Aug 1998 A
5800510 Schmitt Sep 1998 A
5800512 Lentz et al. Sep 1998 A
5800514 Nunez Sep 1998 A
5824050 Karwoski et al. Oct 1998 A
5840240 Stenoien Nov 1998 A
5843173 Shannon et al. Dec 1998 A
5851229 Lentz et al. Dec 1998 A
5851230 Lentz et al. Dec 1998 A
5866217 Stenoien et al. Feb 1999 A
5897587 Martakos et al. Apr 1999 A
5904967 Ezaki et al. May 1999 A
5910168 Myers et al. Jun 1999 A
5918643 Roloff Jul 1999 A
5931865 Silverman et al. Aug 1999 A
5976192 McIntyre et al. Nov 1999 A
6001125 Golds et al. Dec 1999 A
6016848 Egres et al. Jan 2000 A
6027779 Campbell et al. Feb 2000 A
6036724 Lentz et al. Mar 2000 A
6039755 Edwin Mar 2000 A
6042666 Karwoski et al. Mar 2000 A
6053939 Okuda et al. Apr 2000 A
6056970 Greenawalt et al. May 2000 A
6080198 Lentz et al. Jun 2000 A
6099557 Schmitt Aug 2000 A
6159565 Campbell et al. Dec 2000 A
6165211 Thompson Dec 2000 A
6187054 Colone et al. Feb 2001 B1
6203735 Edwin Mar 2001 B1
6267834 Shannon et al. Jul 2001 B1
6287337 Martakos et al. Sep 2001 B1
6319279 Shannon et al. Nov 2001 B1
6328762 Anderson et al. Dec 2001 B1
6338904 Patnaik et al. Jan 2002 B1
6346273 Saettone Feb 2002 B1
6368347 Maini et al. Apr 2002 B1
6416537 Martakos et al. Jul 2002 B1
6428571 Lentz et al. Aug 2002 B1
6436135 Goldfarb Aug 2002 B1
6517571 Brauker et al. Feb 2003 B1
6517858 LeMoel et al. Feb 2003 B1
6521284 Parsons et al. Feb 2003 B1
6534084 Vyakarnam et al. Mar 2003 B1
6541589 Baillie Apr 2003 B1
6547820 Staudenmeier Apr 2003 B1
6589468 Schmitt Jul 2003 B1
6663614 Carter Dec 2003 B1
6712919 Ruefter et al. Mar 2004 B2
6716239 Sowinski Apr 2004 B2
6719783 Lentz et al. Apr 2004 B2
6790226 Edwin et al. Sep 2004 B2
6814753 Schmitt Nov 2004 B2
6827737 Hill et al. Dec 2004 B2
6863686 Shannon et al. Mar 2005 B2
6926735 Henderson Aug 2005 B2
6939377 Jayaraman et al. Sep 2005 B2
7056336 Armstrong et al. Jun 2006 B2
7056387 Van Der Steur Jun 2006 B2
7108701 Evens et al. Sep 2006 B2
7147617 Henderson et al. Dec 2006 B2
7244271 Lentz et al. Jul 2007 B2
7297158 Jensen Nov 2007 B2
7306729 Bacino et al. Dec 2007 B2
7351257 Kaldany Apr 2008 B2
7396363 Frid Jul 2008 B2
7452374 Hain et al. Nov 2008 B2
7510571 Spiridigliozzi et al. Mar 2009 B2
7531611 Sabol et al. May 2009 B2
7553326 Sweet et al. Jun 2009 B2
7560006 Rakos et al. Jul 2009 B2
8029563 House Oct 2011 B2
8637144 Ford Jan 2014 B2
8906087 House Dec 2014 B2
9139669 Xu et al. Sep 2015 B2
9814560 Cully et al. Nov 2017 B2
10357385 Schlaud Jul 2019 B2
20020058991 Schmitt May 2002 A1
20020138129 Armstrong Sep 2002 A1
20030004559 Lentz et al. Jan 2003 A1
20030027775 Wallace Feb 2003 A1
20030060871 Hill et al. Mar 2003 A1
20030100859 Henderson et al. May 2003 A1
20030139806 Haverkost et al. Jul 2003 A1
20030153983 Miller et al. Aug 2003 A1
20040000858 Hwang et al. Jan 2004 A1
20040024442 Sowinski et al. Feb 2004 A1
20040033364 Spiridigliozzi et al. Feb 2004 A1
20040049264 Sowinksi et al. Mar 2004 A1
20040054406 Dubson et al. Mar 2004 A1
20040122507 Henderson Jun 2004 A1
20040182511 Rakos et al. Sep 2004 A1
20040193242 Lentz et al. Sep 2004 A1
20040215337 Hain Oct 2004 A1
20040265352 Kaldany Dec 2004 A1
20050137677 Rush Jun 2005 A1
20050187607 Akhtar et al. Aug 2005 A1
20050203606 VanCamp Sep 2005 A1
20050240261 Rakos Oct 2005 A1
20050249776 Chen et al. Nov 2005 A1
20060041318 Shannon Feb 2006 A1
20070116736 Argentieri et al. May 2007 A1
20070276474 Llanos et al. Nov 2007 A1
20070293808 Williams et al. Dec 2007 A1
20080027534 Edwin et al. Jan 2008 A1
20080097592 Fitzpatrick Apr 2008 A1
20080195026 Kim Aug 2008 A1
20080195079 Moore et al. Aug 2008 A1
20090270973 Chen et al. Oct 2009 A1
20110054586 Mayberry Mar 2011 A1
20120130477 Gessaroli May 2012 A1
20150157444 Cully et al. Jun 2015 A1
20180092733 Cully et al. Apr 2018 A1
Foreign Referenced Citations (42)
Number Date Country
1466165 Jan 2004 CN
1486165 Mar 2004 CN
1976648 Jun 2007 CN
103857416 Jun 2014 CN
0117072 Aug 1984 EP
0256748 Feb 1988 EP
0266035 May 1988 EP
0391586 Oct 1990 EP
656196 Jul 1995 EP
1131113 Feb 2000 EP
1101458 May 2001 EP
1925270 May 2008 EP
2033232 May 1980 GB
1590101 May 1981 GB
2222954 Mar 1990 GB
6343688 Dec 1994 JP
2739420 Mar 1995 JP
8238263 Sep 1996 JP
11099163 Apr 1999 JP
5176947 Jul 2010 JP
5474514 Jun 2011 JP
5925725 Nov 2014 JP
WO-1995010247 Apr 1995 WO
WO-1996007370 Mar 1996 WO
WO-9826731 Jun 1998 WO
WO-2001021107 Mar 2001 WO
WO-2001032382 May 2001 WO
WO-2001067991 Sep 2001 WO
WO-2002013675 Feb 2002 WO
WO-03015837 Feb 2003 WO
WO-2003084440 Oct 2003 WO
WO-2004060209 Jul 2004 WO
WO-2004096307 Nov 2004 WO
WO-2006007214 Jan 2006 WO
WO-2006026725 Mar 2006 WO
WO-2006038031 Apr 2006 WO
WO-2006058322 Jun 2006 WO
WO-2006085044 Aug 2006 WO
WO-2007061787 May 2007 WO
WO-2007113494 Oct 2007 WO
WO-2007127802 Nov 2007 WO
WO-2007137211 Nov 2007 WO
Non-Patent Literature Citations (17)
Entry
Berman M, Pearce W, et al, The use of Gore-Tex E-PTFE bonded to silicone rubber as an alloplastic implant material. Laryngoscope 1986; v96 n5: 480-483.
European Search Report from EP18208417.8, dated Apr. 24, 2019, 8 pages.
GORE® Acuseal Cardiovascular Patch Product Information, Jun. 2014, 40 pages.
International Search Report and Written Opinion for PCT/US2014/068411 dated Feb. 12, 2015, corresponding to U.S. Appl. No. 14/557,927, 9 pages.
International Search Report and Written Opinion for PCT/US2016/035857 dated Aug. 4, 2016, corresponding to U.S. Appl. No. 15/173,361, 11 pages.
LeMatire Expedial Vascular Access Graft Product Information/Instructions For Use.
Lumsden AB, Chen C et al. Nonporous silicone polymer coating of expanded polytetrafluoroethylene grafts reduces graft neointimal hyperplasia in dog and baboon models. Journal of Vascular Surgery 1996; v24 n5: 825-833.
Perma-Seal Dialysis Access Graft Instructions for use.
Perma-Seal Dialysis Access Graft Patient Education Brochure.
Sonoda H, Takamizawa K et al. Coaxial double-tubular compliant arterial graft prosthesis: time-dependent morphogenesis and compliance changes after implantation. J Biomed Mater Res 2003; 65A: 170-181.
Sonoda H, Takamizawa K et al. Small-diameter compliant arterial graft prosthesis: Design concept of coaxial double tubular graft and its fabrication. J Biomed Mater Res 2011; 55: 266-276.
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2014/068411, dated Jun. 16, 2016, 7 pages.
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2016/035857, dated Dec. 14, 2017, 8 pages.
International Search Report and Written Opinion for PCT/US2014/068411 dated Feb. 12, 2015, corresponding to U.S. Appl. No. 14/557,927, 5 pages.
LeMatire Expedial Vascular Access Graft Product Information/Instructions for Use, 3 pages.
Perma-Seal Dialysis Access Graft Instructions for use, 14pages.
Perma-Seal Dialysis Access Graft Patient Education Brochure, 5 pages.
Related Publications (1)
Number Date Country
20190343663 A1 Nov 2019 US
Provisional Applications (1)
Number Date Country
62171694 Jun 2015 US
Continuations (1)
Number Date Country
Parent 15173361 Jun 2016 US
Child 16519078 US